Replies to post #256603 on Anavex Life Sciences Corp (AVXL)

[Amatuer17]

Typically if the topline data is good, companies issue in a hurry and then keep more detailed analysis for a conference.

This also allows them to go to FDA requesting meeting while they do all the analysis.

They will need the next level details to justify that the results are good if the general topline results are not good or very good.